AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25895616
Drug: Cediranib 30mg
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib 30mg oral daily (od)
Trial: 25896788
Drug: 4 hours
RxNorm normalized name: PATCH, TRANSDERMAL 24 HOURS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 hours SHD using a dialysate flow of 500 mL/min
Trial: 25897792
Drug: Lomitapide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomitapide (5 mg to 60 mg a day, maximum)
Trial: 25898341
Drug: Acceptance-based Separated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance-based Separated Family Treatment (ASFT)
Trial: 25898693
Drug: Dermatophagoides mix
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermatophagoides mix (300, 600, 3000, 6000, and 15000 SQ+) administered at weekly intervals with 1 maintenance injection (15000 SQ+) 2 weeks after the last updosing injection.
Trial: 25899176
Drug: Budesonide/formoterol combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol combination (BFC)
Trial: 25899176
Drug: Fluticasone/salmeterol combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone/salmeterol combination (FSC)
Trial: 25899782
Drug: Intratumoral injection
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral injection of adenoviral vector expressing E. coli PNP and intravenous fludarabine (escalating doses of fludarabine: 15, 45, and 75 mg/m(2))
Trial: 25899782
Drug: Intratumoral injection
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral injection of adenoviral vector expressing E. coli PNP and intravenous fludarabine
Trial: 25900065
Drug: Subcutaneous rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous rituximab (all doses)
Trial: 25900065
Drug: Intravenous rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous rituximab 500 mg/m²
Trial: 25900182
Drug: Cixutumumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cixutumumab (10 mg/kg i.v.), Everolimus (10 mg p.o. daily), Octreotide LAR (20 mg i.m. every 21 days)
Trial: 25900467
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of sedatives and analgesics
Trial: 25901095
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg alprazolam given 30 min before a clamp during euglycemia
Trial: 25901095
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg alprazolam given 30 min before a clamp during hypoglycemia
Trial: 25901095
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg alprazolam during euglycemia
Trial: 25901286
Drug: AGS-003 in
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGS-003 in combination with sunitinib
Trial: 25901550
Drug: Life-sustaining treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Life-sustaining treatments (mechanical ventilation, vasopressors, renal replacement therapy)
Trial: 25902842
Drug: idursulfase 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: idursulfase 0.5 mg/kg weekly for one year
Trial: 25903963
Drug: PEI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEI regimen (Cisplatin 20 mg/m2, Etoposide 75 mg/m2, Ifosfamide 1200 mg/m2, day 1 to 4, every 3 weeks)
Trial: 25904000
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (eGFR > 30 ml/min)
Trial: 25904635
Drug: Variant rs705702-G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variant rs705702-G near RAB5B and SUOX
Trial: 25906048
Drug: Breast conserving
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast conserving therapy (BCT) with surgical removal of the tumor (lumpectomy) followed by radiation treatment.
Trial: 25907171
Drug: Budesonide/formoterol 80/4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol 80/4.5 μg one inhalation b.i.d.
Trial: 25907171
Drug: Budesonide/formoterol 160/4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol 160/4.5 μg one inhalation b.i.d.
Trial: 25907171
Drug: Budesonide/formoterol 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol 2 x 160/4.5 μg b.i.d.
Trial: 25907621
Drug: Ipilimumab 10mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab 10mg/kg every 3 weeks for up to four doses, with maintenance therapy every 3 months until disease progression, unacceptable toxic effect, or death.
Trial: 25908679
Drug: Medication incidents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication incidents identified among primary care patients
Trial: 25909192
Drug: 10mg of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg of oral zinc
Trial: 25909513
Drug: Other atypical
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other atypical antipsychotics
Trial: 25911223
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics for pulmonary exacerbation (PEx) treatment
Trial: 25911554
Drug: Bendamustine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine plus bortezomib and prednisone (1.3 mg/m(2) bortezomib twice weekly for 6 weeks, 90 mg/m(2) bendamustine on days 1 and 4)
Trial: 25912075
Drug: Recombinant factor
RxNorm normalized name: Recombinant factor IX
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant factor VIII Fc fusion protein (rFVIIIFc), starting regimen: twice-weekly prophylaxis (Day 1: 25 IU kg(-1); Day 4: 50 IU kg(-1)); adjusted dose (≤ 80 IU kg(-1)) and dosing interval (≥ 2 days) as needed.
Trial: 25915616
Drug: IPTp-MQ (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPTp-MQ (2 doses)
Trial: 25915616
Drug: IPTp-MQ (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPTp-MQ (3 doses) added to CTXp
Trial: 25915780
Drug: IMMU-132 (17.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMMU-132 (17.5 mg/kg; twice weekly × 4 weeks)
Trial: 25915780
Drug: IMMU-132 (dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMMU-132 (dosing schemes: every other week, weekly, or twice weekly)
Trial: 25916910
Drug: Postprandial lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprandial lipid metabolism
Trial: 25917561
Drug: New-generation P2Y₁₂
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New-generation P2Y₁₂ receptor antagonists
Trial: 25918250
Drug: Cetuximab (400mg/m²,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (400mg/m², then 250mg/m²) and trastuzumab (3.0 or 4.0mg/kg, then 1.5 or 2.0mg/kg weekly)
Trial: 25918559
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of sirolimus
Trial: 25918559
Drug: Subconjunctival injection
RxNorm normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival injection of sirolimus
Trial: 25921059
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg by mouth daily
Trial: 25921689
Drug: TDF 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF 150 mg once daily
Trial: 25921689
Drug: TDF 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF 300 mg every 48 hours
Trial: 25921689
Drug: TDF 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF 150 mg once daily and TDF 300 mg every 48 hours
Trial: 25923040
Drug: Postoperative copeptin
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative copeptin levels measured daily until discharge
Trial: 25923040
Drug: Copeptin <2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copeptin <2.5 pmol/L on postoperative day 1
Trial: 25923040
Drug: Copeptin >30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copeptin >30 pmol/L on postoperative day 1
Trial: 25923426
Drug: Concurrent detection
RxNorm normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent detection of pathogens
Trial: 25923549
Drug: AZD9291 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9291 (20 to 240 mg once daily)
Trial: 25923603
Drug: Essential amino-acid
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential amino-acid supplements
Trial: 25924990
Drug: Salmeterol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (50 μg) administered after placebo; 4 weeks of treatment with salmeterol 50 μg twice daily.
Trial: 25924991
Drug: Ipilimumab 3
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 3 mg/kg in combination with paclitaxel (PTX) and carboplatin (CBDCA)
Trial: 25924991
Drug: Ipilimumab 10
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 10 mg/kg in combination with paclitaxel (PTX) and carboplatin (CBDCA)
Trial: 25924991
Drug: Ipilimumab 3
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 3 mg/kg and 10 mg/kg in combination with paclitaxel (PTX) and carboplatin (CBDCA)
Trial: 25925619
Drug: Polatuzumab vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Polatuzumab vedotin (0.1-2.4 mg/kg every 21 days) as a single agent
Trial: 25925619
Drug: Polatuzumab vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Polatuzumab vedotin combined with rituximab (375 mg/m2)
Trial: 25925619
Drug: Polatuzumab vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Polatuzumab vedotin (1.0 mg/kg) in CLL
Trial: 25925619
Drug: Polatuzumab vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Polatuzumab vedotin (2.4 mg/kg) in NHL
Trial: 25925619
Drug: Rituximab combination
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab combination cohort
Trial: 25925673
Drug: High-dose atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose atorvastatin (80 mg/day) for two weeks prior to surgery
Trial: 25926352
Drug: Preoperative capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preoperative capecitabine (825 mg/m² b.i.d. Monday-Friday), oxaliplatin (50 mg/m² weekly), bevacizumab (5 mg/kg on days 1, 15, and 29), and radiation therapy (50.4 Gy) followed by surgery and postoperative FOLFOX plus bevacizumab (5 mg/kg) every 2 weeks for 12 cycles.
Trial: 25926352
Drug: Preoperative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative therapy (capecitabine, oxaliplatin, bevacizumab, and RT) followed by surgery and postoperative FOLFOX plus bevacizumab.
Trial: 25926352
Drug: Preoperative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative therapy followed by surgery and postoperative FOLFOX plus bevacizumab.
Trial: 25926600
Drug: Prophylactic doses
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic doses of danaparoid or fondaparinux for participants with low 4Ts score or intermediate 4Ts score plus negative PF4/H-PaGIA result.
Trial: 25926600
Drug: Therapeutic doses
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic doses of nonheparin anticoagulants for all others.
Trial: 25926858
Drug: Darunavir/cobicistat 800/150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/cobicistat 800/150 mg once daily
Trial: 25927980
Drug: Emergency Medical
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency Medical Services (EMS) treatment for OHCA
Trial: 25928811
Drug: Intravenous ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ferric carboxymaltose (1,000 mg iron)
Trial: 25929250
Drug: Nicoboxil/nonivamide ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicoboxil/nonivamide ointment
Trial: 25929250
Drug: Nicoboxil ointment
RxNorm normalized name: nicoboxil
DrugBank: Nicoboxil (DB12911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicoboxil ointment
Trial: 25929250
Drug: Nonivamide ointment
RxNorm normalized name: Nonivamide
DrugBank: Nonivamide (DB11324)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonivamide ointment
Trial: 25929582
Drug: Axitinib combined
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib combined with cisplatin/gemcitabine (starting dose 5 mg bid, titrated to 2-10 mg bid; cisplatin 80 mg/m2 i.v. every 3 weeks; gemcitabine 1,250 mg/m2 i.v. on days 1 and 8 of each 3-week cycle)
Trial: 25929922
Drug: Ritonavir-boosted darunavir
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir-boosted darunavir monotherapy (mtDRV/rtv)
Trial: 25931518
Drug: Dinaciclib (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinaciclib (20 mg/kg, i.p., three times a week) and MK-2206 (60 mg/kg, orally, three times a week)
Trial: 25933833
Drug: Ilorasertib (540
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilorasertib (540 mg once weekly and 480 mg twice weekly)
Trial: 25933833
Drug: Ilorasertib (oral)
RxNorm normalized name: Ilorasertib
DrugBank: Ilorasertib (DB11694)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilorasertib (oral)
Trial: 25934475
Drug: Combination DFX-deferoxamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination DFX-deferoxamine (DFO)
Trial: 25935574
Drug: GELS
RxNorm normalized name: Gelsolin
DrugBank: Recombinant human plasma gelsolin (DB15746)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GELS
Trial: 25935574
Drug: CDEIS and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDEIS and GELS
Trial: 25935574
Drug: SES-CD and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SES-CD and GELS
Trial: 25935794
Drug: High-dose clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose clarithromycin (2 g/day, oral, days 1-14, every 21 days)
Trial: 25936321
Drug: Apheresis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apheresis treatment with atorvastatin
Trial: 25936984
Drug: Retinal gene
RxNorm normalized name: retinaldehyde
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinal gene therapy
Trial: 25937263
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose alkylating chemotherapy (HDAC) based on BRCA1-like testing
Trial: 25937431
Drug: Dacomitinib (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacomitinib (45 mg) administered via gastrostomy feeding tube (GT) in fasting state and supine position.
Trial: 25937529
Drug: Physician belief
RxNorm normalized name: Ora Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician belief about standard therapy
Trial: 25937868
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg/d in 6-wk cycles (4 wk on treatment followed by 2 wk off treatment)
Trial: 25937868
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg/d
Trial: 25938001
Drug: INV (investigator's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INV (investigator's choice of therapy)
Trial: 25938638
Drug: Gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene therapy with rAAV2/2 RPE65 vector
Trial: 25939066
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (specific dosage and duration not mentioned)
Trial: 25939720
Drug: PNPLA3 rs738409
RxNorm normalized name: SUS SCROFA G.(NC_010447.5) 5087853-5087855GAC>CTG+5087858G>C+5087861T>C+5087864C>G+5087871-5087873CTC>GAA ALTERATION TO EXON 3 OF PNPLA3 GENE IN OSSABAW BREED MINIATURE SWINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNPLA3 rs738409 G allele (148Met) presence in overweight/obese with MetS
Trial: 25939720
Drug: Homozygote G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homozygote G allele in individuals aged below 20 years
Trial: 25942723
Drug: Daclatasvir (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir (30 mg), asunaprevir (200 mg), and beclabuvir (75 mg) fixed-dose combination, administered twice daily for 12 weeks.
Trial: 25942724
Drug: Daclatasvir (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir (30 mg), asunaprevir (200 mg), and beclabuvir (75 mg) with ribavirin (1000-1200 mg/d)
Trial: 25942724
Drug: Daclatasvir (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir (30 mg), asunaprevir (200 mg), and beclabuvir (75 mg) without ribavirin
Trial: 25944628
Drug: HOMA-IR (homeostasis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOMA-IR (homeostasis model assessment-insulin resistance)
Trial: 25944628
Drug: Impaired fasting
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impaired fasting glucose (serum glucose ≥110 mg/dL)
Trial: 25944633
Drug: Full coverage
RxNorm normalized name: GOWN,ISOLATION,FULL COVERAGE XL YELLOW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full coverage for β-blockers, renin-angiotensin system antagonists, and statins without cost sharing
Trial: 25944633
Drug: Usual coverage
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Covera]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual coverage for β-blockers, renin-angiotensin system antagonists, and statins at the current level of insurance coverage
Trial: 25944802
Drug: Sacituzumab govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab govitecan at 12 mg/kg (maximum tolerated dose for cycle 1)
Trial: 25944802
Drug: Sacituzumab govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab govitecan at 8 and 10 mg/kg
Trial: 25947565
Drug: Dinaciclib (escalating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinaciclib (escalating doses on day 1) + Epirubicin (standard dose on day 2)
Trial: 25948664
Drug: Higher usual
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher usual alcohol consumption (10-g increment)
Trial: 25948664
Drug: Higher usual
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher usual alcohol consumption (10-g increment) compared to co-twin
Trial: 25948673
Drug: Serum retinoic
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum retinoic acid (RA) concentration in patients with NAFLD (1.42 ± 0.47 ng/mL)
Trial: 25948673
Drug: Serum retinoic
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum retinoic acid (RA) concentration in patients with NASH (1.14 ± 0.26 ng/mL)
Trial: 25948673
Drug: Serum RA
RxNorm normalized name: Mucor racemosus immunoserum rabbit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum RA concentrations in control subjects with normal glucose tolerance (2.87 ± 0.52 ng/mL)
Trial: 25948673
Drug: Serum RA
RxNorm normalized name: Mucor racemosus immunoserum rabbit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum RA concentrations in NAFLD patients with normal glucose tolerance (1.61 ± 0.37 ng/mL)
Trial: 25948673
Drug: Serum RA
RxNorm normalized name: Mucor racemosus immunoserum rabbit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum RA concentrations in NASH patients with normal glucose tolerance (1.35 ± 0.34 ng/mL)
Trial: 25951716
Drug: DHEA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA supplementation (30 mg, 3 times a day, orally for 3 months)
Trial: 25952795
Drug: Sym004 (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sym004 (12 mg/kg weekly infusions)
Trial: 25952796
Drug: Sandwich-like neoadjuvant
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandwich-like neoadjuvant therapy with bevacizumab (induction therapy with bevacizumab and FOLFOX, concurrent chemoradiotherapy with bevacizumab and consolidation chemotherapy with FOLFOX)